Personalized Medicine Market Forecast 2026-2036: Market to Reach USD 779.4 Billion by 2036 at 6.4% CAGR

NEWARK, DE | The personalized medicine market, valued at USD 393.9 billion in 2025, is poised for substantial expansion as advancements in genomics and biomarker technologies reshape healthcare delivery. Projections indicate the market will reach USD 732.5 billion by 2035, reflecting a robust CAGR of 6.4% over the forecast period. This growth underscores the shift toward tailored treatments that improve efficacy and safety, positioning the personalized medicine market as a cornerstone of modern medicine.

Read Full Report:https://www.futuremarketinsights.com/reports/personalized-medicine-market

Market snapshot: global market 2026 - 2036

Market size 2026? USD 419.1 billion.
Market size 2036? USD 779.4 billion.
CAGR? 6.4%.
Leading product segment(s) and shares: Companion diagnostics and targeted therapeutics hold the largest combined share; diagnostics segment dominates due to its critical role in identifying biomarkers, while therapeutics see high growth from targeted drug development.
Leading application and share: Oncology accounts for the majority of personalized medicine revenue.
Leading end use: Hospitals and clinics lead as primary delivery points for advanced diagnostics and targeted therapies.
Key growth regions: Asia Pacific, led by India and China; North America remains dominant by value.
Top companies: Illumina Inc., Asuragen Inc., Genentech, Inc., Abbott Laboratories, Roche Holding AG, Thermo Fisher Scientific, Danaher Corporation, Guardant Health, Foundation Medicine, Myriad Genetics, Exact Sciences, Tempus AI.
The personalized medicine market is on a steady upward trajectory, building from USD 393.9 billion in 2025 to projected values of USD 474.5 billion in 2028, USD 537.1 billion in 2030, USD 571.5 billion in 2031, USD 647.0 billion in 2033, and USD 732.5 billion in 2035. This year-over-year path highlights the compounding impact of technological advancements and regulatory support in the personalized medicine market.

Why the Market is Growing

The personalized medicine market is expanding due to companion diagnostic mandates from the FDA and EMA, which tie drug approvals to matched testing and create parallel revenue streams. Liquid biopsy adoption is transforming oncology monitoring from periodic imaging to real-time molecular surveillance. Pharmacogenomics integration into electronic health records is broadening prescriber adoption beyond oncology into cardiology and psychiatry.

Segment Spotlight

Product Type

The diagnostics segment dominates the personalized medicine market because of its essential function in pinpointing biomarkers, genetic mutations, and patient-specific disease profiles, especially in oncology, rare diseases, and pharmacogenomics. The therapeutics segment experiences high growth driven by advancements in targeted drug development, gene therapy, and immunotherapy.

Application

Oncology accounts for the majority of revenue in the personalized medicine market, fueled by tumor profiling and biomarker therapies that identify the most effective and least toxic regimens based on genomic profiles. This dominance extends opportunities for pharmaceutical companies to expand pipelines with declining genomic sequencing costs and companion diagnostics.

End Use

The hospitals segment holds a broad portion of the personalized medicine market as it serves as the key hub for delivering advanced diagnostics, genomic tests, and targeted therapies, particularly in oncology, cardiology, and rare diseases. Specialized genomics centers command a significant share through their expertise in advanced genomic sequencing, bioinformatics, and multi-omics, supporting clinical diagnostics for complex conditions.

Drivers, Opportunities, Trends, Challenges

Companion diagnostic mandates and regulatory pull are key drivers in the personalized medicine market, with the FDA approving 12 personalized medicines in 2024, representing 34% of new approvals. Cost deflation in sequencing, now below USD 200 per test, enables wider adoption, while pharma-diagnostics convergence through partnerships accelerates precision medicine scaling.

Opportunities arise from growth investments in oncology and rare disease treatments, where tumor profiling and gene therapies revolutionize care for genetic conditions. Declining sequencing costs and companion diagnostics open pathways for faster drug development, regulatory approvals, and reimbursement for targeted therapies, fostering market expansion globally.

Emerging trends include the integration of data analytics in personalized treatment, using machine learning to process genomic and clinical data for predictive plans, especially in cancer. Direct-to-consumer genetic testing is also rising, offering personalized health insights on disease risk and medication response, driving proactive preventive medicine.

Challenges involve the integration and secure management of diverse data sources like genomics, EHRs, and lifestyle information, hindered by silos in health systems and interoperability issues. This compromises clinical views and raises privacy concerns, while the gap between diagnostic capabilities and available therapies creates value chain imbalances.

Country Growth Outlook (CAGR)

Country

CAGR (2026-2036)

China

7.6%

India

8.2%

Germany

5.8%

UK

5.5%

USA

6.2%

Brazil

6.8%

(Note: France data not specified in analysis.)

Competitive Landscape

The competitive outlook in the personalized medicine market emphasizes predictive analytics and multi-omics approaches to boost diagnostic precision and therapeutic targets. Companies are forming affiliations with biotechnology firms, hospitals, and genomics laboratories to strengthen their presence. Regulatory approvals favor companion diagnostics and targeted therapies, while rapid sequencing technologies and digital health solutions drive innovation. Market share leaders include Illumina Inc. (33.6% to 38.5%), Asuragen Inc. (20.4% to 22.6%), Genentech, Inc. (15.1% to 17.2%), and Abbott Laboratories (4.6% to 6.8%). Recent developments feature SOPHiA GENETICS expanding its AI platform in February 2026, Gilead Sciences advancing antibody-drug conjugates, and Eli Lilly progressing its oral GLP-1 candidate. Other key players encompass Exact Sciences Corporation, Biogen International, Exagen Inc., Genelex Corporation, Precision Biologics, Inc., QIAGEN, Celera Diagnostics LLC, and Dako A/S.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1511

Get Access of Report Sample:https://www.futuremarketinsights.com/reports/sample/rep-gb-1511

Scope of the Report

Quantitative Units: USD 419.1 billion (2026) to USD 779.4 billion (2036), at a CAGR of 6.4%.
Market Definition: Products, technologies, and services that tailor medical treatment to individual patient characteristics, spanning genomic diagnostics, pharmacogenomic testing, companion diagnostics, biomarker-guided therapeutics, and precision digital health platforms.
Product Type Segmentation: Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition and Wellness.
End User Segmentation: Hospitals and Clinics, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Others.
Regions Covered: North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa.
Key Companies Profiled: Roche Holding AG, Illumina Inc., Thermo Fisher Scientific, Danaher Corporation, Abbott Laboratories, Guardant Health, Foundation Medicine, Myriad Genetics, Exact Sciences, Tempus AI.
Forecast Period: 2026 to 2036.

FAQ

What market intelligence does this provide for strategic decision-making? It offers insights across diagnostics, therapeutics, and precision care delivery in the personalized medicine market.

What is the market size estimation and forecast? The personalized medicine market includes 10-year revenue forecasts from 2026 to 2036.

What growth opportunities are mapped? Opportunities are detailed across personalized diagnostics, targeted therapeutics, medical care, and nutrition segments.

Are segment and regional revenue forecasts included? Yes, the report provides segmental breakdowns and regional forecasts for the personalized medicine market.

What competition strategy assessments are covered? Assessments include diagnostics-therapeutics integration models and AI-driven pathology platforms.

How does it analyze regulatory impact? It covers FDA companion diagnostic approvals, EMA guidelines, and Asia Pacific genomic testing frameworks.

What about reimbursement landscape? Tracking is provided across Medicare, NHS, and major commercial payers in the personalized medicine market.

In what formats is the market report delivered? Delivery includes PDF, Excel, PPT, and interactive dashboard formats.

Explore More Related Studies Published by FMI Research:

Pediatric Non-invasive Wearables Market: https://www.futuremarketinsights.com/reports/pediatric-non-invasive-wearables-market

Mobile Diagnostic Sealed MRI Magnets Market: https://www.futuremarketinsights.com/reports/mobile-diagnostic-sealed-mri-magnets-market

Children Appetite Stimulant Market: https://www.futuremarketinsights.com/reports/children-appetite-stimulant-market

AI Oncology Vibe CT Scanners Market: https://www.futuremarketinsights.com/reports/ai-oncology-vibe-ct-scanners-market

Single Use Pump Market: https://www.futuremarketinsights.com/reports/single-use-pump-market

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com

Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

This release was published on openPR.